Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Model analyses risk of death from hepatocellular carcinoma-related factors after liver transplantation

The latest edition of Gastroenterology considers a model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma.

News image

Outcomes of liver transplantation for hepatocellular carcinoma are determined by cancer-related and non-related events.

Treatments for hepatitis C virus infection have reduced non-cancer events among patients receiving liver transplants, so reducing hepatocellular carcinoma related death might be an actionable end point.

Dr Vincenzo Mazzaferro and colleagues from Italy performed a competing-risk analysis to evaluate factors associated with survival of patients with hepatocellular carcinoma, and developed a prognostic model based on features of hepatocellular carcinoma patients before liver transplantation.

The doctors performed multivariable competing-risk regression analysis to identify factors associated with hepatocellular carcinoma-specific death of patients who underwent liver transplantation.

The training set comprized 1018 patients who underwent liver transplantation for hepatocellular carcinoma from 2000 through 2013 at 3 tertiary centers in Italy. 


The cumulative incidence of death was segregated for hepatitis C virus status
Gastroenterology
The validation set comprized 341 consecutive patients who underwent liver transplantation for hepatocellular carcinoma during the same period at the Liver Cancer Institute in Shanghai, China.

The researchers collected pretransplantation data on etiology of liver disease, number and size of tumors, patient level of α-fetoprotein, model for end-stage liver disease score, tumor stage, numbers and types of treatment, response to treatments, tumor grade, microvascular invasion, dates, and causes of death.

Death was defined as hepatocellular carcinoma-specific when related to hepatocellular carcinoma recurrence after transplantation, disseminated extra- and/or intrahepatic tumor relapse and worsened liver function in presence of tumor spread.

The team noted that the cumulative incidence of death was segregated for hepatitis C virus status.

In the competing-risk regression, the sum of tumor number and size, and level of α-fetoprotein were significantly associated with hepatocellular carcinoma-specific death.

The researchers found that 5-year cumulative incidence of non−hepatocellular carcinoma related death was 9% in hepatitis C virus-negative patients, and 18% in hepatitis C virus-positive patients.

For patients with hepatocellular carcinoma to have a 70% chance of hepatocellular carcinoma-specific survival 5 years after transplantation, their level of α-fetoprotein should be <200 ng/mL and the sum of number and size of tumors should not exceed 7.

If the level of α-fetoprotein was 200−400 ng/mL, the sum of the number and size of tumors should be ≤5, and if their level of α-fetoprotein was 400−1000 ng/mL, the sum of the number and size of tumors should be ≤4.

In the validation set, the model identified patients who survived 5 years after liver transplantation with 0.721 accuracy.

The research team developed a model based on level of α-fetoprotein, tumor size, and tumor number, to determine risk of death from hepatocellular carcinoma-related factors after liver transplantation.

Dr Mazzaferro's team concluded, "This model might be used to select end points and refine selection criteria for liver transplantation for patients with hepatocellular carcinoma."

"To predict 5-year survival and risk of hepatocellular carcinoma-related death using an online calculator, please see www.hcc-olt-metroticket.org/."

Gastroenterology 2018: 154 (1): 128–139

06 February 2018

Go to top of page Email this page Email this page to a colleague

 24 May 2018 
Precision medicine for tumors
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 23 May 2018 
High body mass index is and ulcerative colitis
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us